CD19-CD34t metabolically programmed CAR transduced T-cells / Medical University of South Carolina - LARVOL DELTA

Phase 1 dose escalation study of CD34 selected CD19 directed CAR T with metabolic programming in relapsed/refractory B-cell lymphoma. (ASCO 2026) - P1/2 | "Six patients (40%) received tocilizumab (toci) and two (13%) received corticosteroids for CRS management with cumulative administration of 8 doses of toci (mean 0.5 doses/patient) and 20 mg of dexamethasone (mean 1.3 mg/patient) for entire cohort... CD19-CAR-CD34t hybrid T cells showed promising efficacy and durability, with no relapses among patients with CR. There were no occurrences of either ICANS or grade 3+ CRS and limited CRS intervention needed. This is a promising toxicity profile for a CD28 co-stimulated CAR-19, likely owing to a more purified product via CD34 selection."

CAR T-Cell Therapy • P1 data • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD34

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Trial completion date: Sep 2027 ➔ Dec 2026

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Trial completion date: Dec 2026 ➔ Sep 2027

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Trial primary completion date: Sep 2025 ➔ Nov 2026

Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1/2 | N=27 | Recruiting | Sponsor: Medical University of South Carolina | Not yet recruiting ➔ Recruiting | Phase classification: P1b ➔ P1/2

CAR T-Cell Therapy • Enrollment open • Phase classification • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1b | N=27 | Not yet recruiting | Sponsor: Medical University of South Carolina | Trial completion date: Feb 2026 ➔ Dec 2026 | Initiation date: Apr 2023 ➔ Aug 2023 | Trial primary completion date: Feb 2025 ➔ Aug 2025

CAR T-Cell Therapy • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov) - P1b | N=27 | Not yet recruiting | Sponsor: Medical University of South Carolina

CAR T-Cell Therapy • New P1 trial • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • BCL2 • BCL6 • CD19